Research Papers:
Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2420 views | HTML 3177 views | ?
Abstract
Eyra Marien1, Michael Meister2,3, Thomas Muley2,3, Teresa Gomez del Pulgar4, Rita Derua5, Jeffrey M. Spraggins6, Raf Van de Plas6,7, Frank Vanderhoydonc1, Jelle Machiels1, Maria Mercedes Binda8, Jonas Dehairs1, Jami Willette-Brown9, Yinling Hu9, Hendrik Dienemann3,10, Michael Thomas3,11, Philipp A. Schnabel3,12, Richard M. Caprioli6, Juan Carlos Lacal4, Etienne Waelkens5 and Johannes V. Swinnen1
1 KU Leuven – University of Leuven, LKI - Leuven Cancer Institute, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium
2 Thoraxklinik at University Hospital Heidelberg, Translational Research Unit, Heidelberg, Germany
3 TLRC-H – Translational Lung Research Center Heidelberg, Member of The German Center for Lung Research, Heidelberg, Germany
4 Fundación Jiménez Díaz, Division of Translational Oncology, Madrid, Spain
5 KU Leuven – University of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, Leuven, Belgium
6 Vanderbilt University Medical Center, Department of Biochemistry and Mass Spectrometry Research Center, Nashville, TN, USA
7 Delft University of Technology, Delft Center for Systems and Control, Delft, The Netherlands
8 KU Leuven – University of Leuven, LKI - Leuven Cancer Institute, Department of Oncology, Abdominal Surgical Oncology, Leuven, Belgium
9 National Cancer Institute, Centre for Cancer Research, Cancer and Inflammation Program, Frederick, MD, USA
10 Thoraxklinik at University Hospital Heidelberg, Department of Surgery, Heidelberg, Germany
11 Thoraxklinik at University Hospital Heidelberg, Department of Thoracic Oncology, Heidelberg, Germany
12 University of The Saarland, Institut für Allgemeine und Spezielle Pathologie, Homburg/Saar, Germany
Correspondence to:
Johannes V. Swinnen, email:
Keywords: lipidomics, phospholipids, cancer, ELOVL, lung SCC
Received: December 17, 2015 Accepted: January 04, 2016 Published: February 03, 2016
Abstract
Lung cancer is the leading cause of cancer death. Beyond first line treatment, few therapeutic options are available, particularly for squamous cell carcinoma (SCC). Here, we have explored the phospholipidomes of 30 human SCCs and found that they almost invariably (in 96.7% of cases) contain phospholipids with longer acyl chains compared to matched normal tissues. This trait was confirmed using in situ 2D-imaging MS on tissue sections and by phospholipidomics of tumor and normal lung tissue of the L-IkkαKA/KA mouse model of lung SCC. In both human and mouse, the increase in acyl chain length in cancer tissue was accompanied by significant changes in the expression of acyl chain elongases (ELOVLs). Functional screening of differentially expressed ELOVLs by selective gene knockdown in SCC cell lines followed by phospholipidomics revealed ELOVL6 as the main elongation enzyme responsible for acyl chain elongation in cancer cells. Interestingly, inhibition of ELOVL6 drastically reduced colony formation of multiple SCC cell lines in vitro and significantly attenuated their growth as xenografts in vivo in mouse models. These findings identify acyl chain elongation as one of the most common traits of lung SCC discovered so far and pinpoint ELOVL6 as a novel potential target for cancer intervention.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7179